New RNA drug heads to clinic as AIRNA bags $155 million
US biotech AIRNA has secured $155 million in series B financing to advance its lead RNA-editing candidate into human trials and broaden its pipeline of genetic medicines.
The round, co-led by Venrock Healthcare and Forbion Growth, marks a significant endorsement of RNA-editing platforms, particularly at a time when broader market uncertainty continues to challenge early-stage biotechs.
Cambridge, Massachusetts-based AIRNA is developing AIR-001, an investigational therapy that seeks to restore levels of M-AAT protein in patients with alpha-1 antitrypsin deficiency (AATD) — a genetic condition that can result in progressive lung and liver damage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze